You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2024

Bupivacaine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for bupivacaine and what is the scope of patent protection?

Bupivacaine is the generic ingredient in seventeen branded drugs marketed by Hengrui Pharma, Pacira Pharms Inc, Innocoll, Innocoll Pharms, Aspiro, Civica, Eugia Pharma, Hikma Pharms, Hospira, Meitheal, Somerset, Steriscience Speclts, Intl Medicated, Fresenius Kabi Usa, B Braun Medical Inc, Baxter Hlthcare Corp, Huons, Septodont, Amphastar Pharms Inc, and Heron Theraps Inc, and is included in fifty-one NDAs. There are thirty-seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bupivacaine has sixty-nine patent family members in thirty countries.

There are twelve drug master file entries for bupivacaine. Two suppliers are listed for this compound.

Drug Prices for bupivacaine

See drug prices for bupivacaine

Recent Clinical Trials for bupivacaine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Yongtao SunPhase 4
Montefiore Medical CenterN/A
University Hospital "Sestre Milosrdnice"N/A

See all bupivacaine clinical trials

Pharmacology for bupivacaine
Drug ClassAmide Local Anesthetic
Physiological EffectLocal Anesthesia
Medical Subject Heading (MeSH) Categories for bupivacaine
Anatomical Therapeutic Chemical (ATC) Classes for bupivacaine
Paragraph IV (Patent) Challenges for BUPIVACAINE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
EXPAREL Injectable Suspension bupivacaine 133 mg/10 mL 022496 1 2021-12-28
EXPAREL Injectable Suspension bupivacaine 266 mg/20 mL 022496 1 2021-08-20

US Patents and Regulatory Information for bupivacaine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-002 Oct 28, 2011 AP RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-001 May 12, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Hospira BUPIVACAINE HYDROCHLORIDE bupivacaine hydrochloride INJECTABLE;INJECTION 070586-001 Mar 3, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-001 May 12, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Heron Theraps Inc ZYNRELEF KIT bupivacaine; meloxicam SOLUTION, EXTENDED RELEASE;PERIARTICULAR 211988-003 May 12, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for bupivacaine

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-002 Oct 28, 2011 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-001 Oct 28, 2011 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-002 Oct 28, 2011 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-002 Oct 28, 2011 ⤷  Sign Up ⤷  Sign Up
Pacira Pharms Inc EXPAREL bupivacaine INJECTABLE, LIPOSOMAL;INJECTION 022496-002 Oct 28, 2011 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for bupivacaine

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pacira Ireland Limited Exparel liposomal bupivacaine EMEA/H/C/004586
Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds.
Authorised no no no 2020-11-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for bupivacaine

Country Patent Number Title Estimated Expiration
Georgia, Republic of P20094831 CONTROL RELEASE SYSTEM ⤷  Sign Up
South Korea 20220140711 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 ⤷  Sign Up
European Patent Office 1809329 COMPOSITION LOCALE ANESTHESIQUE A DELIVRANCE SOUTENUE CONTENANT AIBS (SUSTAINED LOCAL ANESTHETIC COMPOSITION CONTAINING SAIB) ⤷  Sign Up
Brazil 112022013784 SISTEMAS DE DISTRIBUIÇÃO DE FÁRMACOS DE LIBERAÇÃO PROLONGADA COM IMPUREZAS REDUZIDAS E MÉTODOS RELACIONADOS ⤷  Sign Up
Portugal 1809329 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.